Aurobindo Pharma vs Lupin: share price, P/E, ROE and financials compared
Aurobindo Pharma
Lupin
Aurobindo Pharma and Lupin at a glance
Aurobindo Pharma and Lupin are both listed in Healthcare. Aurobindo Pharma is the larger by market cap, at ₹1.0L Cr against ₹90,914 Cr for Lupin. On valuation, Aurobindo Pharma has the lower price-to-book (2.63× against 3.78×), while Lupin has the lower P/E (17.5× against 26.1×). On returns and margins, Lupin has the higher ROCE (28.3% against 13.5%), the higher ROE (23.9% against 10.7%) and the higher operating margin (28.9% against 20.6%). Over three years, Lupin has faster 3-year sales growth (+19.1% against +10.7% a year) and faster 3-year profit growth (+131.4% against +22.0% a year). Debt-to-equity is similar, 0.22× for Aurobindo Pharma and 0.26× for Lupin.
Key metrics, side by side
| Metric | Aurobindo PharmaAUROPHARMA | LupinLUPIN |
|---|---|---|
| Price (₹) | 1,800.00 | 1,988.10 |
| Market cap (₹ Cr) | 1,03,568 | 90,914 |
| P/E | 26.1× | 17.5× (the lower figure, shaded) |
| P/B | 2.63× (the lower figure, shaded) | 3.78× |
| Dividend yield, trailing | 0.00% | 0.91% (the higher figure, shaded) |
| ROE | 10.7% | 23.9% (the higher figure, shaded) |
| ROCE | 13.5% | 28.3% (the higher figure, shaded) |
| Operating margin (OPM) | 20.6% | 28.9% (the higher figure, shaded) |
| Net margin (NPM) | 10.8% | 16.9% (the higher figure, shaded) |
| Sales CAGR 3Y | +10.7% | +19.1% (the higher figure, shaded) |
| Profit CAGR 3Y | +22.0% | +131.4% (the higher figure, shaded) |
| Debt to equity | 0.22× | 0.26× |
| Interest cover | 15.5× | 17.7× (the higher figure, shaded) |
| Net profit TTM (₹ Cr) | – | 5,206 |
| 1Y return | +55.3% (the higher figure, shaded) | −0.5% |
| Promoter holding | 51.88% | 46.84% |
Aurobindo Pharma vs Lupin: common questions
Which is bigger, Aurobindo Pharma or Lupin?
By market cap, Aurobindo Pharma is bigger at ₹1.0L Cr, against ₹90,914 Cr for Lupin (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Aurobindo Pharma or Lupin?
Aurobindo Pharma trades at a P/E of 26.1× and Lupin at 17.5×. Lupin has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Aurobindo Pharma or Lupin?
Aurobindo Pharma reports a return on equity of 10.7% and Lupin 23.9%. Lupin has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Aurobindo Pharma or Lupin?
Over the last three years: Sales grew +10.7% a year at Aurobindo Pharma and +19.1% at Lupin, so Lupin grew sales faster; profit grew +22.0% a year at Aurobindo Pharma and +131.4% at Lupin, so Lupin grew profit faster. Past growth doesn’t predict future growth.